Thermo Fisher Scientific Inc.
NYSE:TMOMedical - Diagnostics & Research
+$4.45 today
- Market cap
- $256.67B
- Beta
- 0.87
- P/E (TTM)
- 25.3
- EPS (TTM)
- $18.44
- Dividend yield
- 0.39%
Volume 1.99M
Average 2.23M
TMO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Thermo Fisher Scientific Inc.NYSE: TMO
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $2.51B fell 11.6% year over year, behind the -0.8% change in trailing-twelve-month EBITDA. Sequentially, it fell 13.7% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.
Context
- EBITDA amounted to 25.7% of revenue in FY2025, down 1.8 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 20 analysts of $14.59B (+27.2%) for the fiscal year ending Dec 2026, a step up from the -2.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $2.51B-13.7% QoQ
- Last fiscal yearDec 2025
- $11.47B-2.8% YoY
- LTMSep 2026
- $11.24B-0.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.6% | +26.6% | +38.2 pp |
| 1 year | -2.8% | +27.2% | +30.0 pp |
| 3-year CAGR | -1.3% | +12.4% | +13.8 pp |
| 5-year CAGR | +11.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 11.47B USD
- Year-over-year change
- -2.8%
- 4-year CAGR
- -1.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.47B | -2.8% |
| FY2024 | 2024-12-31 | 11.8B | +5.4% |
| FY2023 | 2023-12-31 | 11.2B | -6.3% |
| FY2022 | 2022-12-31 | 11.94B | -0.2% |
| FY2021 | 2021-12-31 | 11.97B | — |
EBITDA vs competitors
How TMO compares with its peers on the latest reported figures
- TMO's LTM Sep 2026 EBITDA of $11.24B is the highest of the 10 companies compared; the peer median is $767M.
- Its year-over-year change of -0.8% is the 5th highest of 10, against a peer median of -1.6%.
- EBITDA amounts to 23.7% of revenue for TMO, versus a peer median of 26.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.24B | -0.8% | -1.3% | 23.7% | |
| LTM Sep 2026 | $7.09B | +3.2% | -9.9% | 27.7% | |
| LTM Jul 2026 | $2.04B | +13.2% | -1.2% | 27.6% | |
| LTM Jun 2026 | $1.31B | +7.1% | +0.1% | 31.6% | |
| LTM Jul 2026 | $950.77M | -10.1% | -0.2% | 20.5% | |
| LTM Jul 2026 | $767M | -6.7% | -13.5% | 26.3% | |
| LTM Jun 2026 | $703.39M | -1.6% | -2.7% | 33.5% | |
| LTM Jun 2026 | $514.7M | -22.7% | — | 19.9% | |
| LTM Sep 2026 | $328.77M | +48.3% | -9.1% | 26.8% | |
| LTM Jun 2026 | $247.7M | -38.6% | -16.4% | 7.1% | |
| Peer median (excluding TMO) | $767M | -1.6% | -5.9% | 26.8% | |
Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.21B | 44.92B | 42.86B | 42.88B | 44.56B |
| Cost of Revenue | 19.58B | 25.9B | 25.66B | 25.15B | 26.32B |
| Gross Profit | 19.63B | 19.01B | 17.19B | 17.73B | 18.24B |
| Gross Margin | 50.1% | 42.3% | 40.1% | 41.3% | 40.9% |
| Research & Development | 1.41B | 1.47B | 1.34B | 1.39B | 1.4B |
| Selling, General & Admin | 7.91B | 9.02B | 8.41B | 8.68B | 8.73B |
| Operating Expenses | 9.32B | 10.49B | 9.75B | 10.07B | 10.13B |
| Depreciation & Amortization | 2.59B | 3.38B | 3.41B | 3.11B | 2.78B |
| EBITDA | 11.97B | 11.94B | 11.2B | 11.8B | 11.47B |
| EBITDA Margin | 30.5% | 26.6% | 26.1% | 27.5% | 25.7% |
| Operating Income | 10.32B | 8.53B | 7.45B | 7.66B | 8.11B |
| Operating Margin | 26.3% | 19.0% | 17.4% | 17.9% | 18.2% |
| Interest Income | 43M | 272M | 879M | 1.08B | 993M |
| Interest Expense | 536M | 726M | 1.49B | 1.65B | 1.42B |
| Other Income / Expenses | (1.48B) | (862M) | (1.21B) | (667M) | (842M) |
| Income Before Tax | 8.84B | 7.66B | 6.24B | 7B | 7.27B |
| Pre-Tax Margin | 22.5% | 17.1% | 14.6% | 16.3% | 16.3% |
| Income Tax Expense | 1.11B | 703M | 284M | 657M | 547M |
| Net Income | 7.73B | 6.95B | 6B | 6.34B | 6.74B |
| Net Margin | 19.7% | 15.5% | 14.0% | 14.8% | 15.1% |
| EPS (Basic) | 19.61 | 17.73 | 15.53 | 16.58 | 17.77 |
| EPS (Diluted) | 19.46 | 17.64 | 15.45 | 16.53 | 17.74 |
| Weighted Avg Shares | 394M | 392M | 386M | 382M | 376M |
| Weighted Avg Shares (Diluted) | 397M | 394M | 388M | 383M | 377M |
Thermo Fisher Scientific Inc.
NYSE:TMO
Intrinsic Alpha fair value
Locked
Current Price
$692.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.